Argus downgrades Abbott Labs stock rating on guidance cut
Covered in this story
What has happened since
- Abbott Laboratories is up 6.6% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Mizuho’s $115 target on $ABT is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Mizuho’s track record →Tracked from this story
BTIG’s $125 target on $ABT is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
BTIG’s track record →Tracked from this story
StoneX’s $120 target on $ABT is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
StoneX’s track record →Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 41 stories mentioning Abbott Laboratories, the earliest published 6 May 2017.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.